In the Pipeline

BY Benjamin Ryan

July 01 2009 12:00 AM ET

Although no major medications are expected to hit the market in the next few months, the drug pipeline does contain a handful of candidates that are reaching the research stage of final clinical trials.

ENTRY INHIBITORS

[Medication Name/Code (with Drug Class), Research Stage, Manufacturer]

' DP-178 (fusion inhibitor), Preclinical, Weizmann Institute
' GP41 inhibitor, Preclinical, Locus Pharmaceuticals
' GSK706769 (CCR5 blocker), Phase I, GlaxoSmithKline
' IC9564 (BA entry inhibitor), Preclinical, Duke University
' INCB15050 (CCR5 blocker), Phase I, Incyte
' MDX-010 (CTLA-4 blocker), Preclinical, Medarex
' PF232798 (CCR5 blocker), Phase II, Pfizer
' PRO-140 (monoclonal antibody), Phase II, Progenics
' Sifuvirtide (fusion inhibitor), Phase IIb, FusoGen
' TBR-220 (CCR5 blocker), Phase I, Tobira
' TBR-652 (CCR5 blocker), Phase I, Tobira
' Ibalizumab TNX-355 (monoclonal antibody), Phase II, Taimed
' TRI-1144 (fusion inhibitor), Preclinical, Trimeris and Roche
' Vicriviroc (CCR5 blocker), Phase III, Schering-Plough
' Zinc finger protein nucleases (CCR5 blockers), Preclinical, Sangamo Biosciences

--------------------

INTEGRASE INHIBITORS

[Medication Name/Code, Research Stage, Manufacturer]

' Beta-diketo acids, Preclinical, University of Parma and University of Sassari
' Elvitegravir (GS-9137), Phase III, Gilead Sciences
' GS-9224, Preclinical, Gilead Sciences
' GSK364735, Phase I, GlaxoSmithKline/Shionogi
' GSK13495172, Phase II, GlaxoSmithKline

--------------------

MATURATION INHIBITORS

[Medication Name/Code, Research Stage, Manufacturer]

' Betulinic acid derivatives, Preclinical, University of North Carolina, Duke University, Vanderbilt University
' Bevirimat (gag processing inhibitor), Phase II, Myriad
' Capsid inhibitors, Preclinical, Achillion
' MPC 9055, Phase II, Myriad
' PA1050040, (gag processing inhibitor), Phase I, Panacos
' RPI-MN, (nAchR receptor inhibitor), Preclinical, ReceptoPharm

--------------------

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

[Medication Name/Code, Research Stage, Manufacturer]

' C-8 quinolinyloxyethyl substitutent, Preclinical, Boehringer Ingelheim
' HBY097 (Pyridinone derivatives), Preclinical, Rutgers University
' IDX899, Phase II, Idenix/GSK
' MV026048, Preclinical, Medivir
' Oligodeoxynucleotides, Preclinical, University of Zurich
' Rilpivirine (TMC-278), Phase III, Tibotec
' RDEA806, Phase IIa, Ardea
' RDEA427, Phase I, Ardea
' RDEA640, Preclinical, Ardea
' Thiazole derivatives, Preclinical, Japan's Institute for Virus Research
' UK-435061, Phase II, Pfizer

--------------------

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

[Medication Name/Code, Research Stage, Manufacturer]

' 4-Ed4T, Preclinical, Kagoshima University
' Amdoxovir (DAPD), Phase II, RFS Pharma
' Apricitabine (ATC), Phase IIb/III, Avexa
' Dexelvucitabine (DFC, formerly Reverset), Phase II, Pharmasset
' DOT (dioxolane thymidine), Phase I, University of Georgia
' Elvucitabine (ACH-126), Phase II, Achillion
' Fosalvudine (alovudine prodrug), Phase II, Heidelberg Pharmaceuticals
' GS-9131, Preclinical, Gilead Sciences
' GS-9148, Preclinical, Gilead Sciences
' IDX12899, Preclinical, Idenix Pharmaceuticals
' IDX12989, Preclinical, Idenix Pharmaceuticals
' Quinolones, Preclinical, Rega Institute
' Racivir, Phase II, Pharmasset
' Thiovir, Preclinical, Adventrx
' TSAO-T derivatives, Preclinical, University of Pittsburgh

--------------------

PK BOOSTERS

[Medication Name/Code, Research Stage, Manufacturer]

' GS-9350, Phase I, Gilead Sciences
' SPI-452, Phase I, Sequoia
' TMC558445, Phase I, Tibotec Pharmaceuticals
' PF-03716539, Phase I, Pfizer

--------------------

PROTEASE INHIBITORS

[Medication Name/Code, Research Stage, Manufacturer]

' GRL-02031, Preclinical, Kumamoto University
' SPI-256, Phase I, Sequoia

--------------------

OTHER CLASSES

[Medication Name/Code (with Drug Class), Research Stage, Manufacturer]

' 1H4 (tat inhibitor), Preclinical, Taras Shevchenko University
' BIT225 (Vpu ion blockers), Phase 1, Biotron Limited
' Histone deacetylase inhibitors, Phase I/II, University of California, San Francisco
' HRG214 (caprine IgG), Preclinical, Vironex
' KP-1461 (viral decay accelerator), Phase II, Koronis
' LEDGF (integrase competers), Preclinical, Catholic University of Leuven
' Poly acrylic acid, Preclinical, Chinese Academy of Science
' RSC-1838, Preclinical, GlaxoSmithKline and Shionogi
' SCY-635 (cyclophilin inhibitor), Phase Ib, Scynexis
' siRNA constructs (rev/tat inhibitors), Preclinical, Beckman Institute
' siRNA, Preclinical, CombiMatrix

AddThis

READER COMMENTS ()

Quantcast